A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Obinutuzumab in Patients with ISN/RPS 2003 Class III or IV Lupus Nephritis
Sponsor: |
Hoffmann-La Roche |
Enrolling: |
Male and Female Patients |
Study Length: |
728 Days |
Clinic Visits: |
12 |
IRB Number: |
AAAP9450 |
U.S. Govt. ID: |
NCT02550652 |
Contact: |
Anca Askanase MD MPH: 212-305-0856 / ada20@cumc.columbia.edu |
The purpose of this study is to test the safety and effectiveness of the study drug Obinutuzumab and to find out what effects, good or bad, it may have as an additional therapy in treating your lupus nephritis symptoms.
This study is closed
Investigator
Anca Askanase, MD, MPH
Have you been diagnosed with lupus? |
Yes |
No |
Have you been diagnosied with lupus nephritis? |
Yes |
No |
Should you qualify for this study, would you agree to remain abstinent or use two adequate methods of contraception? |
Yes |
No |
Are you pregnant or lactating? |
Yes |
No |